

SANOFI SYNTHELABO SA

Form 6-K

March 10, 2004

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**

**PURSUANT TO RULE 13a-16 OR 15d-16  
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of March 2004

Commission File Number: 001-31368

**SANOFI-SYNTHÉLABO**

(Translation of registrant's name into English)

174, avenue de France, 75013 Paris, FRANCE  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F

Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): \_\_\_\_\_

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): \_\_\_\_\_

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes

No

If  Yes marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):  
82-\_\_\_\_\_

**Investor Relations**

Paris, March 10th, 2004

Jean-François Dehecq, Chairman and Chief Executive Officer of Sanofi-Synthelabo will present the Group comments on Aventis<sup>1</sup> Note d'information en réponse (official response) to the share and cash offer on Aventis shares at a meeting for financial analysts, institutional investors and journalists :

Thursday March 11th, 2004 at 14h30 Paris time (GMT+1)  
(1:30 p.m. London time GMT)

**HOTEL D'EVREUX**  
**19 Place Vendôme 75001 PARIS**

The meeting will be conducted in French with simultaneous English translation

The presentation will be accessible on our website : [www.sanofi-synthelabo.com](http://www.sanofi-synthelabo.com)

It will be possible to participate in the conference by dialing the following numbers 10 minutes before the conference starts:

France :	0 800 945 127/0 800 945 126	code : ocean
United Kingdom :	0 800 917 08 64/0 800 358 23 39	code : ocean
USA :	1 800 257 70 63	code : ocean
Germany :	0 800 101 19 65	code : ocean

1) Registered with AMF on March 4th, 2004 under number 04-135

***Investor Relations Department***

<i>Philippe Goupit</i>	<i>Director of Investor Relations</i>
<i>Arnaud Delépine</i>	<i>Investor Relations Europe</i>
<i>Sanjay Gupta</i>	<i>Investor Relations US</i>

***Contacts :***

*E-mail :* [investor-relations@sanofi-synthelabo.com](mailto:investor-relations@sanofi-synthelabo.com)

*Europe* *US*

*Tel : + 33 1 53 77 45 45* *Tel. : 1 212 551 42 93*

*Fax : + 33 1 53 77 42 96* *Fax : 1 212 551 49 92*

**Important Information:** In connection with the proposed acquisition of Aventis, Sanofi-Synthelabo has filed a registration statement on Form F-4 (File no. 333-112314) and will file additional documents with the United States Securities and Exchange Commission (SEC). **Investors are urged to read the registration statement and any other relevant documents filed with the SEC, including all amendments, because they contain important information.** Free copies of the registration statement, as well as other relevant documents filed with the SEC, may be obtained at the SEC's web site at [www.sec.gov](http://www.sec.gov). At the appropriate time, transaction-related documents may be obtained for free from Sanofi-Synthelabo.

In accordance with article 7 of COB regulation n° 2002.04, this press release was transmitted to Autorité des Marchés Financiers before its release.



**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: March 10, 2004

SANOFI-SYNTHÉLABO

By:  /s/ Marie-Hélène Laimay

Name: Marie-Hélène Laimay  
Title: Senior Vice President and Chief Financial  
Officer